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IschemiaMesenchymal stem cells (MSCs) accelerate regeneration of ischemic or injured tissues by stimulation of angio-
genesis through a paracrine mechanism. Tumor necrosis factor-α (TNF-α)-activated MSCs secrete pro-
angiogenic cytokines, including IL-6 and IL-8. In the present study, using an ischemic hindlimb animal model,
we explored the role of IL-6 and IL-8 in the paracrine stimulation of angiogenesis and tissue regeneration by
TNF-α-activated MSCs. Intramuscular injection of conditioned medium derived from TNF-α-treated MSCs
(TNF-α CM) into the ischemic hindlimb resulted in attenuated severe limb loss and stimulated blood perfusion
and angiogenesis in the ischemic limb. Immunodepletion of IL-6 and IL-8 resulted in attenuated TNF-α CM-
stimulated tissue repair, blood perfusion, and angiogenesis. In addition, TNF-α CM induced migration of
human cord blood-derived endothelial progenitor cells (EPCs) through IL-6- and IL-8-dependent mechanisms
in vitro. Intramuscular injection of TNF-α CM into the ischemic limb led to augmented homing of tail vein-
injected EPCs into the ischemic limb in vivo and immunodepletion of IL-6 or IL-8 from TNF-α CM attenuated
TNF-α CM-stimulated homing of EPCs. In addition, intramuscular injection of recombinant IL-6 and IL-8 proteins
resulted in increased homing of intravenously transplanted EPCs into the ischemic limb and improved blood per-
fusion in vivo. These results suggest that TNF-α CM stimulates angiogenesis and tissue repair through an increase
in homing of EPCs through paracrine mechanisms involving IL-6 and IL-8.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Ischemic disease is the end stage of peripheral vascular disease,
resulting in damage or dysfunction of tissues and tissue loss [1]. Ischemic
disease has been reported to affect nearly 80 million members of the
population worldwide [2]. Currently, due to angiogenesis-stimulating
ability of stem cells, stem cell-based therapies have become a promising
strategy in treatment of patients with ischemic disease. [3]. Accumulat-
ing evidence suggests that circulating endothelial progenitor cells
(EPCs) originate from the bonemarrow home to sites of tissue injury, fa-
cilitating neovascularization, and promoting regeneration of the injured
tissues [4]. According to one report, EPCs can integrate into blood vessels
and stimulate neovascularization of the ischemic limbs and hearts in an-
imal models of hindlimb ischemia and cardiac infarction [5]. Therefore,tumor necrosis factor-α; TNF-α
Cs; EPCs, endothelial progenitor
y, School of Medicine, Pusan
o, Republic of Korea. Tel.: +82
ights reserved.mobilization and recruitment of bone marrow-derived stem/progenitor
cells are critical for ischemia-induced neovascularization. Exogenously
administered EPCs have been reported to improve left ventricular ejec-
tion fraction after acute myocardial infarction [6,7]; However, because
patients at the highest cardiovascular risk have the lowest number and
poorest migratory and homing capacity of endogenous EPCs, the use of
autologous EPCs for neovascularization in the clinical setting may
prove less effective [8]. Therefore, the ability to increase the homing of
exogenously administered EPCs to speciﬁc target sites may potentially
lead to the improvement of the therapeutic efﬁcacy of EPCs for ischemic
diseases.
Mesenchymal stem cells (MSCs) can be isolated from diverse adult
tissues, including bone marrow, adipose tissues, umbilical cord blood,
and amniotic membrane [9]. They possess stem cell properties, such
as self renewal capacity, long term viability, and potential for differenti-
ation into mesodermal lineages, including adipocytes, osteocytes,
chondrocytes, and muscle cells [10–12]. In addition to their capacity to
differentiate intomultiple cell lineages,MSCs play a key role in tissue re-
generation through secretion of trophic factors that regulate the local
immune system, ﬁbrosis, apoptosis, and angiogenesis [13–15]. Many
studies have demonstrated that transplantation of MSCs improves
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disease models [16,17]. These studies suggest that MSCs increased
blood perfusion and reduced tissue necrosis in ischemic models
through stimulation of angiogenesis. MSC-derived paracrine factors
have been reported to be largely responsible for MSC-stimulated
neovascularization and tissue regeneration [18,19]. However, the mo-
lecularmechanisms associatedwith the paracrine action ofMSCs in vas-
cular regeneration are still elusive.
Tumor necrosis factor-α (TNF-α), a pro-inﬂammatory cytokine, is
expressed in ischemic and injured tissues [20]. TNF-α plays a key
role not only in inﬂammatory response but also in repair processes of
injured tissues [21]. Knockout of TNF-α receptor p75 has been reported
to attenuate neovascularization in the hindlimb ischemia animal model
and a reduction in the number of circulating bonemarrow-derived EPCs
is responsible for poor neovascularization [22]. TNF-α-treated human
adipose tissue-derived MSCs (hASCs) have been shown to secrete vari-
ous protein factors, including cytokines, extracellular matrix, proteases,
and protease inhibitors [23]. In addition, conditioned medium derived
from TNF-α-treated hASCs (TNF-α CM) accelerated cutaneous wound
healing and angiogenesis through IL-6- and IL-8-dependent mecha-
nisms [24]. However, the involvement of EPCs in TNF-αCM-induced an-
giogenesis and repair of ischemic tissues has not been explored.
To demonstrate the possibility of therapeutic application of TNF-α
CM in regeneration of injured tissues, we investigated the effects of
TNF-α CM on tissue repair, EPC homing, and angiogenesis in an ische-
mic hindlimb murine model. In addition, we explored the question of
whether IL-6 and IL-8 play a role in TNF-α CM-stimulated tissue repair,
EPC homing, and angiogenesis in vivo.
2. Materials and methods
2.1. Materials
α-Minimum essentialmedium, trypsin, and Hank's balanced salt so-
lution were purchased from Invitrogen (Carlsbad, CA). Recombinant
human TNF-α, IL-6, IL-8, and VEGF proteins were purchased from R&D
Systems (Minneapolis, MN). Enzyme-linked immunosorbent assay
(ELISA) kits and neutralizing monoclonal antibodies for human IL-6,
IL-8, and VEGF were purchased from BD Biosciences (Bedford, MA).
Normal mouse IgG was purchased from Millipore (Billerica, MA). Anti-
bodies against von Willebrand Factor (vWF) (ab6994) and α-SMA
(ab5694) were purchased from Abcam PLC (Cambridge, UK).
2.2. Cell culture
Subcutaneous adipose tissues were obtained from elective surgical
procedures with the patient's consent as approved by the institutional
review board of Pusan National University Hospital and hASCswere iso-
lated as previously described [25]. In brief, adipose tissues were washed
at least three timeswith sterile PBS and treatedwith an equal volume of
collagenase type I suspension (1 g/L of Hank's balanced salt solution
buffer with 1% bovine serum albumin) for 60 min at 37 °C with inter-
mittent shaking. Floating adipocytes were separated from the stromal-
vascular fraction by centrifugation at 300 ×g for 5 min. The pelleted
stromal-vascular fraction was re-suspended in α-minimum essential
medium supplementedwith 10% fetal bovine serum, 100 U/mL penicil-
lin, and 100 μg/mL streptomycin, and cells were cultured for 4–5 days
until they reached conﬂuence and were deﬁned as passage “0.” The
passage number of hASCs used in these experiments was 3–10. The
hASCs were positive for CD29, CD44, CD73, CD90, and CD105, whereas
they were negative for CD31, CD34, and CD45 [26].
Human EPCswere isolated from human umbilical cord blood, which
was collected in disposable sterile pyrogen-free bags (Green Cross,
Yongin, Korea) containing anticoagulant. Written informed consent
was obtained from all donors as approved by the institutional review
board of Pusan National University Hospital. Mononuclear cells wereisolated from the blood using Histopaque-1077 (Sigma-Aldrich,
Switzerland), as previously described [27]. Cells were seeded on culture
dishes coated with 0.1% gelatin (Sigma-Aldrich, St. Louis, MO) and
maintained in an endothelial cell basal medium-2 (EBM-2) (Clonetics,
San Diego, CA) supplemented with EGM-2 MV SingleQuots containing
5% fetal bovine serum (FBS), human VEGF-1, human ﬁbroblast growth
factor-2, human epidermal growth factor, insulin-like growth factor-1,
and ascorbic acid. After four days in culture, non-adherent cells were re-
moved and adherent cells were trypsinized and re-plated at a density of
1 × 106 per well through day 7 [27].
2.3. Preparation of conditioned medium
To obtain control CMand TNF-αCM, hASCswere cultured in 150-mm
diameter culture dishes until they reached sub-conﬂuence and were
washed twice with Hank's balanced salt solution for removal of the
serum component. The cells were incubated in 20 mL serum-free
α-minimum essential medium in the absence or presence of
carrier-free recombinant human TNF-α (10 ng/mL) for 48 h. Condi-
tioned medium were collected and centrifuged at 3000 rpm for
10 min using a MF 300 centrifuge (Hanil Science Industrial Co., Ltd.,
Inchon, Korea) for removal of cell debris.
2.4. Immunodepletion of IL-6 and IL-8 from TNF-α CM
For immunodepletion of IL-6 and IL-8 from TNF-α CM, aliquots
(30 μL) of a suspension (50% slurry) of protein G-agarose beads
(Sigma-Aldrich) in PBS were mixed with 0.5 μg of anti-IL-6 and/or
anti-IL-8 antibodies or control mouse antibody (Millipore, Billerica,
MA) at 4 °C for 1 hwith intermittent shaking. After recovery by centrifu-
gation, beadswerewashed three times and used for immunodepletion of
IL-6 and IL-8. TNF-α CM (1 mL) was incubated with protein G-agarose
beads immobilized with anti-IL-6 and/or anti-IL-8 antibodies or control
mouse antibody for 1 h at 4 °C. Immune complexes absorbed to protein
G-agarose beads were precipitated by centrifugation. Resultant superna-
tants were collected and used immediately for experiments.
2.5. Hindlimb ischemia, cell transplantation, and blood ﬂow measurement
All animal experiments were performed according to protocols ap-
proved by the Institutional Animal Care and Use Committee of Pusan
National University School of Medicine. Athymic nude mice (age 8–
10 wk andweighing17–22 g)were anesthetizedwith 50 mg/kg pento-
barbital i.p. for operative resection of one femoral artery and laser
Doppler perfusion imaging. The femoral artery was excised from its
proximal origin as a branch of the external iliac artery to the distal
point where it bifurcates into the saphenous and popliteal arteries.
TNF-α CM, control CM, and HBSS buffer (60 μL each) were injected
intramusculary into three sites (20 μL/each site) of the gracilis muscle
in the medial thigh immediately after surgery. Conditioned medium
or HBSS bufferwas injected three times perweek for fourweeks. To elu-
cidate the role of IL-6 and IL-8 in TNF-α CM-stimulated in vivo
vasculogenesis and tissue repair, the ischemic limbs were injected
with IL-6- and IL-8-depleted TNF-α CM or recombinant IL-6 and IL-8
proteins. The extent of necrosis in the ischemic hindlimb was recorded
on day 28 after surgery. The scores for necrosis were evaluated as fol-
lows: 0, limb salvage; 1, toes amputation; 2, foot amputation; and 3,
limb amputation. Blood ﬂow of the ischemic and normal limbwasmea-
sured using a laser Doppler perfusion imaging (LDPI) analyzer (Moor
Instruments Ltd., Devon, UK) on days 0, 7, 14, 21, and 28 after induction
of hindlimb ischemia. The perfusion of the ischemic and non-ischemic
limb was calculated on the basis of colored histogram pixels. Red and
blue colors indicate high and low perfusion, respectively. Blood perfu-
sion is expressed as the LDPI index representing the ratio of ischemic
versus non-ischemic limb blood ﬂow. A ratio of 1 before operation indi-
cates equal blood perfusion of both legs.
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For histological and immunostaining of the tissue specimens,
hindlimb muscles were removed, formalin-ﬁxed, and parafﬁn-
embedded. Three sections measuring 6 μm in thickness were taken
from the parafﬁn-embedded specimens at 150 μm intervals, stained
with hematoxylin and eosin (H&E), observed, and photographed with a
microscope (Axioimager M2, Carl Zeiss, Heidenheim, Germany). Endo-
thelial cells and smooth muscle cells were immunostained with rabbit
anti-vWF and rabbit anti-α-SMA antibodies. The specimens were incu-
bated with Alexa 488 goat anti-rabbit or Alexa 568 goat anti-rabbit sec-
ondary antibodies, followed by washing and mounting in Vectashield
medium (Vector Laboratories) with 4′,6-diamidino-2-phenylindole
(DAPI) for visualization of nuclei. The stained sections were visualized
by laser scanning confocalmicroscopy (Olympus FluoViewFV1000). Cap-
illary density and the number of arterioles/arteries were assessed by
counting the number of CD31-positive and α-SMA-positive features per
high power ﬁeld (×400). The numbers of CD31-positive and α-SMA-
positive cells were quantiﬁed by two independent observers blinded to
the experimental conditions in nine randomly chosen microscopic ﬁelds
from three serial sections in each tissue block.
2.7. Cell migration assay
Migration of EPCs was assayed using a disposable 96well chemotaxis
chamber (Neuro Probe, Inc., Gaithersburg, MD). Brieﬂy, EPCs wereFig. 1. Effects of TNF-α CMonbloodperfusion and tissue necrosis in the hindlimb ischemiamuri
of mouse hindlimbs on day 0 and 28 after injection of Hank's balanced salt solution (HBBS), con
(B) Quantitative analysis of the blood perfusion recoverymeasured by LDPI analyzer. The LDPI rat
per each experimental group). *, P b 0.05 vs control CM. #, P b 0.05 vs HBSS. (C) Statistical analharvested with 0.05% trypsin containing 0.02% EDTA, washed once, and
suspended in EBM-2 at a concentration of 2 × 105 cells/ml. Amembrane
ﬁlter with 8-μm pores of the chemotaxis chamber was pre-coated over-
night with 20 μg/ml rat-tail collagen at 4 °C, an aliquot (100 μL) of EPCs
suspensionwas loaded into the upper chamber, and TNF-αCMor control
CM was then placed in the lower chamber. After incubation of the cells
for 12 h at 37 °C, the ﬁlters were disassembled, and the upper surface
of each ﬁlter was scraped free of cells by wiping it with a cotton swab.
The number of cells that had migrated to the lower surface of each ﬁlter
was determined by counting the cells in four locations undermicroscopy
at ×100 magniﬁcation after staining with hematoxylin and eosin.
2.8. Cell tracking analysis
EPCs were labeled with the long-lasting CellTracker CM-DiI
according to the manufacturer's instructions. The CM-DiI-labeled EPCs
(1 × 106 cells) were transplanted into the hindlimb ischemia animal
model by intravenous tail vein injection immediately after surgery,
followed by direct injection of TNF-α CM, recombinant IL-6/IL-8 pro-
teins, or vehicles (60 μL each) into the ischemic limbs. Three days
after cell transplantation, the adductor muscle of the ischemic leg was
isolated, formalin-ﬁxed, and parafﬁn-embedded. For quantitative anal-
yses, three sections measuring 6 μm in thickness were taken from the
specimens at 150 μm intervals. CM-DiI-labeled cells were counted in
three randomly chosen microscopic ﬁelds from three serial sections in
each tissue block.nemodel. (A) Representative photographs and color-coded laserDoppler perfusion images
trol CM, or TNF-α CM. The white box indicates the feet, where blood ﬂowwas measured.
iowas calculated as the ratio of ischemic to nonischemic hindlimb blood perfusion. (n = 17
ysis of the necrosis score on day 28. Data indicate mean ± SD (n = 17). *, P b 0.05.
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The results of multiple observations are presented as mean ± SD.
For multivariate data analysis, group differences were assessed with
one-way or two-way ANOVA, followed by Scheffé's post hoc test.
3. Results
3.1. Intramuscular injection of TNF-α CM stimulates blood perfusion of the
ischemic hindlimb and inhibits ischemic tissue damage
To explore the therapeutic impact of TNF-α CM on ischemic tissue
injury, we determined the effect of TNF-α CM on angiogenesis and tis-
sue repair in an ischemic hindlimb animal model. TNF-α CM was ad-
ministered by intramuscular injection into the ischemic hindlimb, and
blood ﬂowwasmeasured over a period of four weeks using a LDPI ana-
lyzer. Intramuscular injection of TNF-α CM into the ischemic hindlimbFig. 2. Effects of TNF-α CMon angiogenesis and vasculogenesis in themouse hindlimb ischemia
blood vessels (red color) of the ischemic limbs injectedwith HBSS, control CM, or TNF-α CMon
thewhite boxes are shown in themiddle panels. (B) Quantiﬁcation of vWF-positive capillaries in
arteries in the ischemic limb by immunohistochemistry analysis. *, P b 0.05; #, P b 0.01. (n = 1resulted in signiﬁcantly improved blood perfusion, as determined by
LDPI (Fig. 1A and B). LDPI ratio showed a signiﬁcant increase in mice
injected with TNF-α CM, as compared with the control experimental
groups in which control CM or saline were injected (Fig. 1B). Injection
of control CM also signiﬁcantly increased LDPI ratio after day 21; how-
ever the stimulatory effect of control CM on blood perfusion was less
potent than that of TNF-α CM. TNF-α CM dose-dependently stimulated
blood perfusion of ischemic hindlimbwith a maximal increase upon in-
tramuscular injection of 60 μL TNF-α CM (Figure I in the online-only
Data Supplement). In addition, injection of TNF-α CM resulted in sig-
niﬁcantly inhibited tissue necrosis and amputation, as demonstrated
by reduced necrosis score four weeks after induction of ischemia, as
compared with control groups (Fig. 1C). Histological analysis showed
necrosis of the ischemic limb in HBSS-injected limbs, and injection of
TNF-α CM resulted in reduced muscle necrosis, compared with control
groups, which were injected with HBSS or control CM (Figure II in the
online-only Data Supplement).model. (A) Immunostaining of vWF-positive capillaries (green color) andα-SMA-positive
day 28. Nuclei (blue)were counterstainedwith DAPI. Magniﬁed images of the areaswithin
the ischemic limb by immunohistochemistry analysis. (C) Quantiﬁcation ofα-SMA-positive
7 per each group).
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stimulate angiogenesis in vivo, we performed immunostaining for de-
termination of capillary density in ischemic muscle. Signiﬁcantly higher
vWF-positive capillary density was observed in the ischemic limb
transplanted with TNF-α CM than in the control groups, which were
injectedwith either control CMor saline buffer (Fig. 2A and B). The den-
sities of α-SMA-positive blood vessels were also increased in the ische-
mic limb injected with TNF-α CM, as compared with the control groups
(Fig. 2A and C). These ﬁndings of increased densities of vWF-positive
capillary and α-SMA-positive arterioles/arteries after TNF-α CM injec-
tion are consistent with the increase in blood perfusion and reduction
of necrosis in the TNF-α CM-injected ischemic limb.
3.2. TNF-α CM stimulates blood perfusion and inhibits necrosis of the
ischemic hindlimb in an IL-6- and IL-8-dependent mechanisms
We have previously reported that immunodepletion of IL-6 or IL-8
from TNF-α CM resulted in abrogated TNF-α CM-stimulated cutaneous
wound healing [24]. To determine whether or not these cytokines are
responsible for TNF-α CM-inhibited ischemic tissue damage, we next
explored the effects of IL-6- or IL-8-depleted TNF-α CM on repair of
the ischemic hindlimb. Both IL-6 and IL-8 could be hardly detected in
control CM, whereas high concentrations of IL-6 (8.9 ± 1.5) and IL-8
(10.1 ± 0.9) were detected in TNF-α CM. Both IL-6 and IL-8 were
depleted from TNF-α CM by immunoprecipitation with antibodies spe-
ciﬁc for IL-6 and IL-8, respectively (Figure III in the online-only Data
Supplement). TNF-α CM-stimulated blood perfusion in the ischemic
limb was attenuated by depletion of IL-8 and/or IL-6 from TNF-α CM
(Fig. 3A). Intramuscular injection of TNF-α CM resulted in a time-
dependent increase of LDPI ratio and immunodepletion of either IL-6Fig. 3. Role of IL-6 and IL-8 in TNF-α CM-improved blood perfusion and tissue necrosis in the is
control CM, TNF-α CM, or IL-6- and/or IL-8-depleted TNF-α CM on day 28. (B) Quantitative an
ratio of ischemic to nonischemic hindlimb blood perfusion. (n = 12 per group). *, P b 0.05 vs co
(n = 12). *, P b 0.05.or IL-8 resulted in abrogated TNF-α CM-stimulated increase of LDPI
ratio. These results suggest that IL-6 and IL-8 are largely responsible
for TNF-α CM-stimulated blood perfusion (Fig. 3B). In addition,
immunodepletion of IL-6 or IL-8 resulted in abrogated TNF-α CM-
inhibited tissue necrosis and amputation, as shown by reduced necrosis
score four weeks after induction of ischemia (Fig. 3A and C).
3.3. Depletion of IL-6 and IL-8 from TNF-α CM blocked TNF-α
CM-stimulated angiogenesis in the ischemic limb
To explore the question of whether or not IL-6 and IL-8 are involved
in TNF-α CM-stimulated angiogenesis in the ischemic limb, we
performed immunostaining in order to examine the effects of IL-6- or
IL-8-depleted TNF-α CM on capillary density in ischemic muscle. As
shown in Fig. 4A, TNF-α CM-stimulated formation of vWF-positive
capillary blood vessels was markedly diminished by depletion of IL-6 or
IL-8. Depletion of IL-6 or IL-8 resulted in consistent attenuation of the
TNF-α CM-stimulated increase of vWF-positive blood vessels (Fig. 4A
and B). In addition, the TNF-α CM-induced increase of α-SMA-positive
blood vessel densities was attenuated by depletion of IL-6 or IL-8 from
TNF-α CM (Fig. 4A and C), suggesting a principal role for IL-6 and IL-8
in TNF-α CM-stimulated angiogenesis and blood perfusion in the ische-
mic limb.
3.4. TNF-α CM stimulates homing and engraftment of EPCs into the
ischemic limb in an IL-6- and IL-8-dependent mechanisms
To explore whether EPCs are involved in the TNF-α CM-stimulated
angiogenesis in vivo,we examined the effect of TNF-α CMon chemotac-
tic migration of EPCs in vitro. As shown in Fig. 5A, TNF-α CM stimulatedchemic limb. (A) Representative photographs and LDPI of a mouse hindlimb injected with
alysis of blood perfusion recovery measured by LDPI. The LDPI ratio was calculated as the
ntrol CM. (C) Statistical analysis of the necrosis score on day 28. Data indicate mean ± SD
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fect of TNF-α CM were more potent than that of control CM. To clarify
whether IL-6 and IL-8 are involved in the TNF-α CM-stimulated migra-
tion of EPCs, we examined the effects of IL-6- or IL-8-depleted TNF-α
CMonmigration of EPCs. As shown in Fig. 5B, TNF-α CM-stimulatedmi-
gration of EPCswasmarkedly attenuated by immunodepletion of IL-6 or
IL-8 from TNF-α CM. In addition, recombinant IL-6 and IL-8 proteins
also induced migration of EPCs.
We next examined the question of whether intramuscular injection
of TNF-α CM into the ischemic limb can affect homing and engraftment
of EPCs into the ischemic hindlimb. To trace engraftment of exogenously
transplanted EPCs into the ischemic limb, EPCs were labeled with CM-
DiI, a ﬂuorescent tracking dye, followed by i.v. injection of CM-DiI-
labeld EPCs and intramuscular injection of TNF-α CM. Sections of the is-
chemic hindlimb muscle were visualized under confocal microscopy
and cell engraftment was quantiﬁed. Engraftment of EPCs into the is-
chemic hindlimb muscle was quantiﬁed by counting CM-DiI-positive
cells on day 3 after i.v. injection of CM-DiI-labeled EPCs. The number
of CM-DiI-positive cells showed an increase in the TNF-α CM-injected
group, compared with the HBSS-injected group. Immunodepletion of
IL-6 or IL-8 from TNF-α CM resulted in attenuated TNF-α CM-induced
engraftment of human EPCs (Fig. 5C and D). In addition, intramuscular
injection of recombinant IL-6 or IL-8 proteins stimulated engraftment
of CM-DiI-positive cells into the ischemic limb. Furthermore, DM-DiI-
positive cells exhibited vWF-positive staining in TNF-α CM-injected
tissues on day 28 after transplantation of CM-DiI-labeled EPCs into the
ischemic limbs (Fig. 5E). These results suggest that TNF-α CM promotes
homing and engraftment of EPCs into newly formed capillaries through
IL-6- and IL-8-dependent mechanisms.Fig. 4.Role of IL-6 and IL-8 in TNF-α CM-stimulated angiogenesis and vasculogenesis. (A) Immu
color) in the ischemic limbs on day 28 after muscular injection of control CM or TNF-α CM
counterstained with DAPI, and overlaid images are shown. (B) Quantiﬁcation of vWF-positive
α-SMA-positive arteries in the ischemic limb by immunohistochemistry analysis. *, P b 0.05 vsTo support involvement of IL-6 and IL-8 in TNF-α CM-stimulated
neovascularization in the ischemic limbs, we next examined the ques-
tion of whether intramuscular injection of recombinant IL-6 and IL-8
proteins into ischemic hindlimbs can stimulate neovascularization
in vivo. We found that intramuscular injection of IL-6 or IL-8 proteins
resulted in a signiﬁcantly increased blood perfusion in the ischemic
limbs four weeks after induction of ischemia (Fig. 6A and B). Injection
of recombinant IL-8 protein exhibited higher densities of vWF-positive
capillaries and α-SMA-positive vessels than injection of IL-6 protein
(Fig. 6C). Co-injection of recombinant IL-6 and IL-8 proteins did not
increase further blood perfusion and capillary and vessel densities, com-
paredwith the experimental groups injectedwith either IL-6 or IL-8 pro-
tein. Taken together, these results suggest that IL-6 and IL-8 are largely
responsible for TNF-α CM-stimulated neovascularization through pro-
motion of homing of EPCs into ischemic tissues, albeit IL-6 and IL-8 do
not fully account for TNF-α CM-stimulated neovascularization.
4. Discussion
In the current study, we demonstrate that TNF-α CM stimulated che-
motacticmigration and in vivo homing of human EPCs through IL-6- and
IL-8-dependent mechanisms. In addition, intramuscular injection of
TNF-α CM promoted angiogenesis in the ischemic limb through mecha-
nisms involving IL-6 and IL-8. According to one report, signiﬁcantly in-
creased chronic lesion volumes, worse long-term functional outcome,
and impaired angiogenesis were observed in IL-6 knockout mice in a
brain stroke animal model [28]. The level of IL-6 was signiﬁcantly up-
regulated in the serum and the ischemic adductormuscle of hindlimb is-
chemic mice and systemic level of IL-6 determined the angiogenicnostaining of vWF-positive capillaries (green color) andα-SMA-positive blood vessels (red
immunodepleted with control, anti-IL-6, and anti-IL-8 antibodies. Nuclei (blue) were
capillaries in the ischemic limb by immunohistochemistry analysis. (C) Quantiﬁcation of
control CM; #, P b 0.01 vs control Ab. (n = 12 per each group).
Fig. 5. Role of IL-6 and IL-8 in TNF-α CM-stimulated in vitro migration and in vivo homing of EPCs. (A) Dose-dependent effects of control CM and TNF-α CM on chemotactic migration of
EPCs. Data indicate mean ± SD (n = 4). #, P b 0.05. (B) Role of IL-6 and IL-8 in TNF-α CM-stimulated migration of EPCs. Chemotactic migration of EPCs in response to IL-6- or IL-8-de-
pleted TNF-α CM, recombinant IL-6, IL-8, VEGF, and HBSS buffer (control) was examined. Data indicate mean ± SD (n = 4). *, P b 0.05; #, P b 0.05 vs control. (C) Role of IL-6 and IL-8 in
TNF-α CM-stimulated in vivo homing of EPCs. The ischemic limbswere injected TNF-α CM immunodepletedwith control, anti-IL-6, and anti-IL-8 antibodies, or recombinant IL-6 and IL-8
proteins, and HBSS buffer (control). Homing of EPCs into the ischemic limbs was quantiﬁed by confocal microscopic analysis of tissue specimens on day 3 after transplantation of intra-
venously transplanted CM-DiI-labeled EPCs. Overlaid images of nuclei (DAPI, blue color) and EPCs (red color) are shown. Bar = 50 μm. Representative images from eight different mice
are shown (n = 8 per each condition). (D) The number of CM-DiI-positive cells per high power ﬁledwas quantiﬁed. Data indicatemean ± SD. *, P b 0.05; #, P b 0.05 vs control. (n = 8).
(E) Incorporation of EPCs into endothelial vessels. Overlaid image of vWF (endothelial cells), CM-DiI (EPCs), and DAPI (nuclei) is shown andwhite arrow indicates CM-DiI-positive endo-
thelial cells in TNF-α CM-injected ischemic limbs. Bar = 25 μm.
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portant modulatory role in lung angiogenesis [30]. IL-6 stimulated
endothelial cell proliferation and differentiation into capillary-like
structures and induced full angiogenic activity in vivo [31]. In addition,
IL-6 stimulated angiogenesis of circulating blood-derived EPCs in vitro
[32]. In addition to IL-6, up-regulation of IL-8/CXCL8 and related cyto-
kines upon inﬂammation and ischemia have been reported [33,34]. IL-
8 directly enhanced endothelial cell survival, proliferation, and angio-
genesis [35,36]. IL-8 was induced in the myocardium after ischemia
and reperfusion in vivo [34]. IL-8 stimulates angiogenesis through en-
hancement of endothelial cell survival, and proliferation [35] and it
plays an important role in myocardial neovascularization, protecting
against cardiomyocyte apoptosis, and functional cardiac recovery by
stimulation of homing of EPCs into ischemic myocardium after acute
myocardial infarction [37]. Therefore, these results suggest that both
IL-6 and IL-8 promote blood perfusion and repair of ischemic tissues
by stimulating the chemotactic migration and angiogenesis of not
only mature endothelial cells but also EPCs.Accumulating evidence suggests thatMSCs secrete various angiogen-
ic cytokines such as vascular endothelial growth factor (VEGF), IGF-1,
angiopoietin-1, and stromal cell-derived factor-1 (SDF-1) [38–40]. Con-
ditionedmedium derived fromMSCs stimulated migration of endotheli-
al cell and tube formation [41]. Using liquid chromatography-coupled
with tandem mass spectrometry analysis, we reported that TNF-α
CM contained high concentrations of various cytokines and chemokines,
including IL-6 and IL-8, CXCL2, CXCL5, CXCL6, CXCL10, monocyte
chemotactic protein-1, matrix metalloprotease-1, plasminogen activator
inhibitor-1, cathepsin L, pentraxin-related protein 3, and complement
factors [23]. In addition, treatment with TNF-α has been shown to stim-
ulate secretion of VEGF, hepatocyte growth factor, and insulin-like
growth factor I fromASCs [42]. Treatmentwith TNF-α has been reported
to stimulate VEGF secretion up to 1.5 fold in ASCs [42]. However, we
could not detect VEGF in control CM and TNF-α treatment did not signif-
icantly increase VEGF secretion in hASCs. Furthermore, pre-treatment of
TNF-α CM with an anti-VEGF neutralizing antibody did not abrogate
TNF-α CM-stimulated migration of EPCs (Figure III in the online-only
Fig. 6. Effects of recombinant IL-6 and IL-8 proteins in blood perfusion and tissue necrosis in the ischemic hindlimbmurinemodel. (A) Representative photographs and laser Doppler per-
fusion image (LDPI) ofmouse hindlimbs on day 0 and 28 after daily injection of 60 μL Hank's balanced salt solution (HBBS), TNF-α CM, IL-6 (10 ng/mL), IL-8 (10 ng/mL), and IL-6 plus IL-8
(each 10 ng/mL). (B) Quantitative analysis of the blood perfusion recoverymeasured by LDPI. The LDPI ratiowas calculated as the ratio of ischemic to nonischemic hindlimb blood perfusion.
(n = 8). *, P b 0.05 vs control (HBSS). (n = 8). (C) Quantiﬁcation of vWF-positive capillaries and α-SMA-positive arteries in the ischemic limb. *, P b 0.05 vs control (HBSS). (n = 8).
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stimulated EPC migration and neovascularization. Furthermore, it is
possible to hypothesize that exogenously added TNF-α can directly af-
fect blood perfusion and tissue repair. However, this possibility can be
excluded because intramuscular injection of recombinant TNF-α did
not increase blood perfusion of ischemic hindlimbs (Figure IV in the
online-only Data Supplement). In this study, we showed that recombi-
nant IL-6 and IL-8 proteins stimulated chemotactic migration of EPCs,
in vivo homing of transplanted EPCs, and blood perfusion in the ischemic
limb. However, IL-6 and IL-8 proteins could not fully recapitulate TNF-α
CM-stimulated EPC migration, homing, and blood perfusion, whereas
immunodepletion of either IL-6 or IL-8 from TNF-α CM abrogated
TNF-α CM-stimulated neovascularization, and in vitro migration and
in vivo homing of EPCs. These results suggest that both IL-6 and IL-8
are essentially needed for TNF-α CM-stimulated neovascularization as
parts of the synergy complex, although IL-6 and IL-8 proteins could
not complete the synergy complex. Therefore, it is conceivable that pro-
teases, growth factors, and other paracrine factors secreted from hASCs
may be implicated in TNF-α CM-facilitated vasculogenesis and tissue
repair in concert with IL-6 and IL-8 as parts of a synergy complex, albeit
clariﬁcation of the functional role of other paracrine factors in TNF-α
CM-stimulated regeneration of ischemic tissues is needed further.
The current study provides evidence that intramuscular injection of
TNF-α CM enhanced blood perfusion and inhibited tissue necrosis in
the ischemic hindlimb. In addition, the number of proliferating cells
was increased in the TNF-α CM-injected ischemic hindlimb. TNF-α
CM induced an increase in the number of vWF-positive capillaries andα-SMA-positive arteries/arterioles in the ischemic limb. Consistently,
we have shown that topical application of TNF-α CM resulted in accel-
eratedwound healing in a cutaneouswound animalmodel by stimulat-
ing re-epithelialization, proliferation, and angiogenesis [24]. These
results suggest that TNF-α CM will be useful for neovascularization
and regeneration of not only cutaneous wounds but also peripheral ar-
tery disease.
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